Clinical trials: Oral Bacterial Infection
Cholera, Vibrio Cholerae Infection
Immune Response to a Delayed Second Dose of Oral Cholera Vaccine
Immune response to a delayed second dose of oral cholera vaccine A randomized, controlled, non-inferiority immunogenicity trial in Conakry, The Republic of Guinea
- Trial name
- NCT05453253
- Testing
- Delayed second dose of oral cholera vaccine, Euvichol-Plus, Oral cholera vaccine, Euvichol-Plus, according to manufacturer notice
- Where
- Guinea
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- Epicentre
Cholera
Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata
The purpose of the study is to confirm the safety and immunogenicity of the oral killed bivalent cholera vaccine in adult and pediatric volunteers in Eastern Kolkata, West Bengal, India.
- Trial name
- NCT00119197
- Testing
- killed whole cell oral cholera vaccine, Heat Killed E. coli
- Where
- India
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Allergic Bronchopulmonary Aspergillosis
A Prospective Study on Optimizing Treatment for ABPA
This study is being done to evaluate the efficacy of treatment using oral glucocorticoid, anti-fungal agent, anti-IgE mAb for patient with ABPA.
- Trial name
- NCT05129033
- Testing
- Prednisone tablet, itraconazole, Omalizumab
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Bacterial Infections
A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study
This is a phase 1, single-center, randomized, placebo-controlled, double-blind, multiple ascending-dose study to assess the safety, tolerability, and PK of oral TP-271 in healthy adult subjects.
- Trial name
- NCT03450187
- Testing
- TP-271
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Tetraphase Pharmaceuticals, Inc
Preterm Labour
N-Acetyl Cysteine for Prevention of Preterm Birth
The antioxidant effect of N-Acetyl cysteine can abort the inflammatory cascade responsible for initiation of preterm labour especially among patients with reccurent preterm birth and patients having bacterial vaginosis
- Trial name
- NAC (NCT00568113)
- Testing
- acetylcysteine in arm 1
- Where
- Egypt
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Assiut University
Streptococcal Infections, Saliva Altered
Efficacy of Propolis Varnish Against Oral Biofilm
This study aims to evaluate the effectiveness of a varnish containing 15% of green propolis on Streptococcus mutans in saliva and biofilm.
- Trial name
- NCT02052973
- Testing
- Propolis varnish
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Risk Reduction
Blood Donor CVD 5000
This is an open-label, non-randomized study. Volunteers will be vaccinated with the typhoid oral vaccine, Vivotif. Vivotif has been licensed by the Food and Drug Administration (FDA) for travelers to developing countries.
- Trial name
- NCT03971669
- Testing
- Vivotif Typhoid Oral Vaccine
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Adverse Reaction to Cholera Vaccine, Cholera Vaccination Reaction
Extended Dose Intervals With Oral Cholera Vaccine in Cameroon
The primary aim of this project is to determine changes in the vibriocidal geometric mean titers (GMT) in subjects who receive the second dose of oral cholera vaccine (OCV) at different intervals: 2 weeks, 6 months, or 11 months…
- Trial name
- NCT03719066
- Testing
- killed whole cell oral cholera vaccine
- Where
- Cameroon
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Typhoid
Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults
This study is to investigate the safety, tolerability and immunogenicity of the typhoid fever vaccine candidate M01ZH09 manufactured at commercial scale, at a new manufacturing facility.
- Trial name
- NCT00679172
- Testing
- Dose of 5.0 x 10^9 CFU (Cohort 1), Dose of 7.5 x 10^9 CFU (Cohort 2), Dose of 1.1 x 10^10 CFU (Cohort 3)
- Where
- 3 sites in United States
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Cholera (Disorder)
VAXCHORA Pediatric Study to Assess Safety and Immunogenicity
VAXCHORA (Cholera Vaccine, Live, Oral) is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1.
- Trial name
- NCT03220737
- Testing
- VAXCHORA (Cholera Vaccine, Live, Oral)
- Where
- 10 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Candidiasis, Oral
Evaluation of the Effect of Different Cleaning and Disinfection Procedures on the Involvement of Candida Species
Individuals may experience tooth loss as a result of trauma, periodontal destruction, lack of adequate bone support and clinically dental mobility.
- Trial name
- NCT03894839
- Testing
- glutaraldehyde disinfection and microwave application, Chlorhexidine gluconate disinfection and microwave application, Sodium hypochlorite disinfection and microwave application
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yuzuncu Yil University
Cholera Vaccination Reaction
Phase 1b Ascending Dose Study of PanChol in Healthy Volunteers
Cholera is a serious diarrheal disease that can be fatal within hours of onset. The current available cholera vaccines to prevent the disease are not very effective.
- Trial name
- PanChol (NCT07107516)
- Testing
- PanChol
- Where
- Zambia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Cholera, Typhoid
Studies of Immune Responses to Orally Administered Vaccines in Developing Country
The efficacy and immunogenicity of enteric vaccines have generally been found to be lower in children in the developed than in the developing countries.
- Trial name
- NCT01019083
- Testing
- Control, Zinc Sulphate, Albendazole and Secnidazole
- Where
- Bangladesh
- Volunteers
- 1,016 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Bacterial Infections
P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants
A Phase 1, Open-Label, Drug-drug Interaction, and Randomized, Double-blind, Controlled, Multiple-dose Pharmacokinetics and Safety Study of Xeruborbactam Oral Prodrug (QPX7831) in Combination with Ceftibuten in Healthy Adult…
- Trial name
- NCT06079775
- Testing
- Xeruborbactam Oral Prodrug, Ceftibuten
- Where
- Australia
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Qpex Biopharma, Inc.
Infections, Bacterial
Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg)
Primary objective:To study the absolute bioavailability, distribution and elimination parameters of flucloxacillin from two oral formulations of flucloxacillin in healthy male and/or female subjects.
- Trial name
- NCT00358371
- Testing
- flucloxacillin 250 mg, flucloxacillin 500 mg
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hidradenitis Suppurativa, Periodontal Diseases
Hidradenitis Suppurativa and Periodontal Diseases
Hidradenitis suppurativa or Verneuil's disease (HS) is a neglected and often overlooked chronic inflammatory skin disease. Nevertheless, it is frequent (1% of the general population) and deeply affects quality of life in patients…
- Trial name
- HSPDA (NCT03553888)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Infections, Bacterial
A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose
This is a phase 1, non-randomized, open label, single-dose, two-period, cross-over study. This study will utilize 14C radiolabeled GSK1322322 to investigate the recovery, excretion, and pharmacokinetics of GSK1322322 in 6 healthy…
- Trial name
- NCT01663389
- Testing
- GSK1322322 1000 mg containing radioactive 14C-GSK1322322, GSK1322322 1200 mg containing radioactive 14C-GSK1322322
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Bacterial
A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects
GSK2251052 ((S)-3-(aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole hydrochloride) is a Gram negative antibacterial compound currently in development for the treatment of hospital acquired Gram negative…
- Trial name
- NCT01262885
- Testing
- GSK2251052
- Where
- Australia
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Periodontal Diseases, Dental Plaque
Oral Health Literacy Tailored Communication
The purpose of this study to investigate attitude, oral health literacy and psychological factors in order to evaluate if these factors are important for oral health in adults.
- Conditions
- Periodontal Diseases, Dental Plaque, Dental Calculus, Sialorrhea
- Trial name
- NCT01118143
- Testing
- Tailored oral health literacy instruction
- Where
- 2 sites in Norway
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- University of Tromso
Oral Bacterial Infection, Oral Infection
Effects of Mouthrinse on the Microbiome of the Oral Cavity and GI Tract
The purpose of this research study is to identify the effects of 2 over-the-counter mouthwashes on bacteria and 3 viruses in the participant's mouth and gut.
- Conditions
- Oral Bacterial Infection, Oral Infection, Microbial Colonization, Viral Infection
- Trial name
- Microbiome (NCT05603650)
- Testing
- Lumineux Oral Essentials rinse, Listerine rinse
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine